Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Fulgent Genetics, Inc. (FLGT)

38.04   -0.19 (-0.5%) 09-24 14:56
Open: 37.87 Pre. Close: 38.23
High: 38.1799 Low: 37.335
Volume: 253,328 Market Cap: 1,151(M)
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 38.43 - 38.8 38.8 - 39.02
Low: 36.55 - 37.03 37.03 - 37.32
Close: 37.48 - 38.28 38.28 - 38.76

Technical analysis

as of: 2022-09-23 4:24:09 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 52.44     One year: 57.9
Support: Support1: 37.33    Support2: 31.06
Resistance: Resistance1: 44.9    Resistance2: 49.58
Pivot: 41.63
Moving Average: MA(5): 39.24     MA(20): 42.26
MA(100): 52.04     MA(250): 65.21
MACD: MACD(12,26): -3     Signal(9): -2.9
Stochastic oscillator: %K(14,3): 5.1     %D(3): 4.3
RSI: RSI(14): 26
52-week: High: 109.55  Low: 37.33
Average Vol(K): 3-Month: 307 (K)  10-Days: 307 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ FLGT ] has closed above bottom band by 6.1%. Bollinger Bands are 16.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 23 Sep 2022
DEADLINE ALERT for TWTR, PLTR, and FLGT: The Law Offices of Frank R. Cruz Reminds Investors of Class Acti - Benzinga

Thu, 22 Sep 2022
Fulgent Genetics, Inc. Class Action Notice: Robbins LLP - GlobeNewswire

Thu, 22 Sep 2022
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fulgent Genetics (FLGT) Investors with Significant Losses to Contact the Firm's Attorneys, DOJ- and SEC-Related Investigations Securities Fraud Case Filed - GlobeNewswire

Wed, 21 Sep 2022
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fulgent Genetics, Inc. (FLGT) Investors - ACROFAN USA

Wed, 21 Sep 2022
CLASS ACTION UPDATE for ABT, SMFR and FLGT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on B - Benzinga

Wed, 21 Sep 2022
FULGENT GENETICS, INC. (NASDAQ: FLGT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulgent Genetics, Inc. (NASDAQ: FLGT) - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 30 (M)
Shares Float 20 (M)
% Held by Insiders 29.4 (%)
% Held by Institutions 45 (%)
Shares Short 1,510 (K)
Shares Short P.Month 1,450 (K)

Stock Financials

EPS 12.11
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 43.11
Profit Margin (%) 42.4
Operating Margin (%) 57.6
Return on Assets (ttm) 26.5
Return on Equity (ttm) 35
Qtrly Rev. Growth -18.4
Gross Profit (p.s.) 25.67
Sales Per Share 30.56
EBITDA (p.s.) 18.27
Qtrly Earnings Growth -85.7
Operating Cash Flow 429 (M)
Levered Free Cash Flow 383 (M)

Stock Valuations

PE Ratio 3.13
PEG Ratio -0.2
Price to Book value 0.88
Price to Sales 1.24
Price to Cash Flow 2.68

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.